Regeneration of Human Infarcted Heart Muscle by Intracoronary Autologous Bone Marrow Cell Transplantation in Chronic Coronary Artery Disease

Strauer, Bodo E.; Brehm, Michael; Zeus, Tobias; Bartsch, Thomas; Schannwell, C. M.; Antke, Christine; Sorg, Rüdiger V.; Kögler, Gesine; Wernet, Peter; Müller, Hans‐Wilhelm; Köstering, Matthias

doi:10.1016/j.jacc.2005.01.069

Cited by 351 publications

(203 citation statements)

References 33 publications

Supporting

Mentioning

182

Contrasting

Unclassified

Order By: Relevance

“…As in animal models, they found a reduction in infarct size, an increase in LV function, and wall motion velocity in the treatment group. No change was obvious in the nonrandomized control group (116). Only few other studies with a small number of patients are further reported for stem cell therapy in this indication.…”

Section: Chronic Myocardial Infarction/coronary Total Occlusionmentioning

confidence: 82%

Endothelial progenitor cells: Implications for cardiovascular disease

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Chronic Myocardial Infarction/coronary Total Occlusionmentioning

confidence: 82%

Endothelial progenitor cells: Implications for cardiovascular disease

et al. 2008

View full text Add to dashboard Cite

show abstract

“…A randomized trial in patients with chronic MI showed that LVEF increased by 15% at 3 months post intracoronary BMC therapy, whereas LVEF reduced 1.0% at the same period in control patients. 35 Moreover, this benefit can be sustained for 2.5 years after MI. 36 One or more years after BMC transfer, significantly reduced LVEDV, LVESV, and infarct size were evidenced in treated patients, which suggested that BMC might attenuate left ventricular remodeling after acute MI.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Intracoronary Autologous Bone Marrow‐Derived Cell Transplantation in Patients With Acute Myocardial Infarction: Insights From Randomized Controlled Trials With 12 or More Months Follow‐Up

Zhang

Sun

Zhang

et al. 2010

Clinical Cardiology

View full text Add to dashboard Cite

Background: Until now there was no systematic review concerning the chronic effects of intracoronary bone marrow-derived cell (BMC) transplantation in patients with acute myocardial infarction (MI). Hypothesis: Improvement of cardiac function in patients with acute MI post BMC transplantation might last longer than 12 months. Methods: We searched MEDLINE, EMBASE, and the Cochrane database through June 2009. Eligible studies were randomized controlled trials of intracoronary BMC transfer in acute MI patients with follow-up duration equal to or longer than 12 months. Results: A total of 8 trials involving 725 participants were identified. Compared with controls, BMC transplantation significantly improved left ventricular ejection fraction (LVEF) by 4.37% (95% confidence interval [CI]: 2.66%-6.08%; P < 0.00001), reduced left ventricular end-diastolic volume (LVEDV) by 5.71 mL (95% CI: 2.03-9.40 mL; P = 0.002), left ventricular end-systolic volume (LVESV) by 8.94 mL (95% CI: 4.22-13.66 mL; P = 0.0002), and infarct size by 2.42% (95% CI: 1.33%-3.51%, P < 0.00001). Bone marrowderived cell treatment also significantly reduced the risk of death (relative risk [RR]: 0.33, 95% CI: 0.13-0.89; P = 0.03), while the risk of reinfarction was similar between the 2 groups (RR: 0.62, 95% CI: 0.09-4.12; P = 0.62). Subgroup analysis showed that the BMC transplantation-induced LVEF increase was more significant in patients age <55 and with cells transferred 6 or 7 days after MI. Conclusion: Beneficial effects of intracoronary BMC transplantation could last more than 12 months in acute MI patients.

show abstract

“…The cell transplantation demonstrated enhanced myocardial perfusion and cardiac function in ischemic hearts of patients with acute or chronic myocardial infarction. [8][9][10][11][12][13] ADSCs contain self-renewing stem cells capable of differentiating in vitro toward osteogenic, adipogenic, myogenic, and chondrogenic lineages when treated with established lineage-specific factors. 14,15 ADSCs have several advantages over other types of stem cells, such as easy accessibility, minimal morbidity upon harvest, and feasibility of extracting clinically relevant numbers of stem cells.…”

Section: Introductionmentioning

confidence: 99%

In vitro cardiomyogenic differentiation of adipose‐derived stromal cells using transforming growth factor‐β1

Gwak

Bhang

Yang

et al. 2009

Cell Biochemistry & Function

View full text Add to dashboard Cite

Transplanting stem cells differentiated towards a cardiac lineage can regenerate cardiac muscle tissues to treat myocardial infarction. In this study, we tested the hypothesis that transforming growth factor-b1 (TGF-b1) induces cardiomyogenic differentiation of adiposederived stromal cells (ADSCs) in vitro. Rat ADSCs were cultured with TGF-b1 (10 ng ml À1 ) for 2 weeks in vitro. ADSCs cultured without TGF-b1 served as a control. The mRNA expression of cardiac-specific gene was induced by TGF-b1, while the control culture did not show cardiac-specific gene expression. Immunocytochemical analyses showed that a small fraction of ADSCs cultured with TGF-b1 for 2 weeks stained positively for cardiac myosin heavy chain (MHC) and a-sarcomeric actin. Flow cytometric analyses showed that the proportion of cells expressing cardiac MHC increased with TGF-b1. However, no mesenchymal differentiation (e.g., osteogenic and adipogenic differentiation) was detected other than cardiomyogenic differentiation. These results showed that TGF-b1 induce ADSC cardiomyogenic differentiation in vitro, which could be useful for myocardial infarction stem cell therapy.

show abstract

Regeneration of Human Infarcted Heart Muscle by Intracoronary Autologous Bone Marrow Cell Transplantation in Chronic Coronary Artery Disease

Abstract: These results demonstrate that functional and metabolic regeneration of infarcted and chronically avital tissue can be realized in humans by bone marrow mononuclear cell transplantation.

Cited by 351 publications

References 33 publications

Endothelial progenitor cells: Implications for cardiovascular disease

Endothelial progenitor cells: Implications for cardiovascular disease

Efficacy and Safety of Intracoronary Autologous Bone Marrow‐Derived Cell Transplantation in Patients With Acute Myocardial Infarction: Insights From Randomized Controlled Trials With 12 or More Months Follow‐Up

In vitro cardiomyogenic differentiation of adipose‐derived stromal cells using transforming growth factor‐β1

Contact Info

Product

Resources

About